Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets

Giovanni Rossi, Maria Marta Minervini, Angelo Michele Carella, Chiara de Waure, Francesco di Nardo, Lorella Melillo, Giovanni D'Arena, Gina Zini, Nicola Cascavilla

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Despite a high remission rate, a significant number of patients with acute myeloid leukemia (AML) relapse. Thus, the evaluation of minimal residual disease (MRD) in AML is an important strategy to better identify high risk patients. Most sensitive methodology to detect MRD is molecular polymerase chain reaction (PCR) but its applicability is restricted to AML with leukemia-specific molecular targets (e.g. AML1-ETO, CBFB-MYH11, MLL, FLT-3). In our study, MRD was monitored at different time points with both MFC and WT1-RNA quantification in 23 AML patients who did not present specific molecular targets. As previously published, we considered values of 10 -3 (0.1%) in MFC and 90 WT1-RNA ×10 4 ABL copies as optimal thresholds. Receiver operating characteristics (ROC) analysis was used to confirm these data. To realize the methodology that better identify high risk patients, an analysis of sensitivity, specificity, predictive values (PV) and likelihood ratio (LR) was provided and similar results were showed. MRD levels ≥10 -3 in MFC as well MRD levels ≥90 WT1-RNA copies in RQ-PCR, identify risk groups of patients with poor prognosis. Therefore, MFC and WT1-RNA quantification showed a comparable capacity in terms of technical performance and clinical significance to identify high risk patients who eventually relapsed.

Original languageEnglish
Pages (from-to)401-406
Number of pages6
JournalLeukemia Research
Volume36
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Residual Neoplasm
Acute Myeloid Leukemia
Flow Cytometry
RNA
Polymerase Chain Reaction
ROC Curve
Leukemia
Recurrence
Sensitivity and Specificity

Keywords

  • Acute myeloid leukemia
  • Flow-cytometry
  • Leukemia-associated immunophenotypes
  • Minimal residual disease
  • WT1-RNA

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. / Rossi, Giovanni; Minervini, Maria Marta; Carella, Angelo Michele; de Waure, Chiara; di Nardo, Francesco; Melillo, Lorella; D'Arena, Giovanni; Zini, Gina; Cascavilla, Nicola.

In: Leukemia Research, Vol. 36, No. 4, 04.2012, p. 401-406.

Research output: Contribution to journalArticle

@article{94ed73ff46d44124823337b23d537773,
title = "Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets",
abstract = "Despite a high remission rate, a significant number of patients with acute myeloid leukemia (AML) relapse. Thus, the evaluation of minimal residual disease (MRD) in AML is an important strategy to better identify high risk patients. Most sensitive methodology to detect MRD is molecular polymerase chain reaction (PCR) but its applicability is restricted to AML with leukemia-specific molecular targets (e.g. AML1-ETO, CBFB-MYH11, MLL, FLT-3). In our study, MRD was monitored at different time points with both MFC and WT1-RNA quantification in 23 AML patients who did not present specific molecular targets. As previously published, we considered values of 10 -3 (0.1{\%}) in MFC and 90 WT1-RNA ×10 4 ABL copies as optimal thresholds. Receiver operating characteristics (ROC) analysis was used to confirm these data. To realize the methodology that better identify high risk patients, an analysis of sensitivity, specificity, predictive values (PV) and likelihood ratio (LR) was provided and similar results were showed. MRD levels ≥10 -3 in MFC as well MRD levels ≥90 WT1-RNA copies in RQ-PCR, identify risk groups of patients with poor prognosis. Therefore, MFC and WT1-RNA quantification showed a comparable capacity in terms of technical performance and clinical significance to identify high risk patients who eventually relapsed.",
keywords = "Acute myeloid leukemia, Flow-cytometry, Leukemia-associated immunophenotypes, Minimal residual disease, WT1-RNA",
author = "Giovanni Rossi and Minervini, {Maria Marta} and Carella, {Angelo Michele} and {de Waure}, Chiara and {di Nardo}, Francesco and Lorella Melillo and Giovanni D'Arena and Gina Zini and Nicola Cascavilla",
year = "2012",
month = "4",
doi = "10.1016/j.leukres.2011.11.020",
language = "English",
volume = "36",
pages = "401--406",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "4",

}

TY - JOUR

T1 - Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets

AU - Rossi, Giovanni

AU - Minervini, Maria Marta

AU - Carella, Angelo Michele

AU - de Waure, Chiara

AU - di Nardo, Francesco

AU - Melillo, Lorella

AU - D'Arena, Giovanni

AU - Zini, Gina

AU - Cascavilla, Nicola

PY - 2012/4

Y1 - 2012/4

N2 - Despite a high remission rate, a significant number of patients with acute myeloid leukemia (AML) relapse. Thus, the evaluation of minimal residual disease (MRD) in AML is an important strategy to better identify high risk patients. Most sensitive methodology to detect MRD is molecular polymerase chain reaction (PCR) but its applicability is restricted to AML with leukemia-specific molecular targets (e.g. AML1-ETO, CBFB-MYH11, MLL, FLT-3). In our study, MRD was monitored at different time points with both MFC and WT1-RNA quantification in 23 AML patients who did not present specific molecular targets. As previously published, we considered values of 10 -3 (0.1%) in MFC and 90 WT1-RNA ×10 4 ABL copies as optimal thresholds. Receiver operating characteristics (ROC) analysis was used to confirm these data. To realize the methodology that better identify high risk patients, an analysis of sensitivity, specificity, predictive values (PV) and likelihood ratio (LR) was provided and similar results were showed. MRD levels ≥10 -3 in MFC as well MRD levels ≥90 WT1-RNA copies in RQ-PCR, identify risk groups of patients with poor prognosis. Therefore, MFC and WT1-RNA quantification showed a comparable capacity in terms of technical performance and clinical significance to identify high risk patients who eventually relapsed.

AB - Despite a high remission rate, a significant number of patients with acute myeloid leukemia (AML) relapse. Thus, the evaluation of minimal residual disease (MRD) in AML is an important strategy to better identify high risk patients. Most sensitive methodology to detect MRD is molecular polymerase chain reaction (PCR) but its applicability is restricted to AML with leukemia-specific molecular targets (e.g. AML1-ETO, CBFB-MYH11, MLL, FLT-3). In our study, MRD was monitored at different time points with both MFC and WT1-RNA quantification in 23 AML patients who did not present specific molecular targets. As previously published, we considered values of 10 -3 (0.1%) in MFC and 90 WT1-RNA ×10 4 ABL copies as optimal thresholds. Receiver operating characteristics (ROC) analysis was used to confirm these data. To realize the methodology that better identify high risk patients, an analysis of sensitivity, specificity, predictive values (PV) and likelihood ratio (LR) was provided and similar results were showed. MRD levels ≥10 -3 in MFC as well MRD levels ≥90 WT1-RNA copies in RQ-PCR, identify risk groups of patients with poor prognosis. Therefore, MFC and WT1-RNA quantification showed a comparable capacity in terms of technical performance and clinical significance to identify high risk patients who eventually relapsed.

KW - Acute myeloid leukemia

KW - Flow-cytometry

KW - Leukemia-associated immunophenotypes

KW - Minimal residual disease

KW - WT1-RNA

UR - http://www.scopus.com/inward/record.url?scp=84857234866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857234866&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.11.020

DO - 10.1016/j.leukres.2011.11.020

M3 - Article

VL - 36

SP - 401

EP - 406

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 4

ER -